Abstract
Purpose Although haploinsufficiency of ANKRD11 is among the most common genetic causes of neurodevelopmental disorders, the role of rare ANKRD11 missense variation remains unclear. We characterized the clinical, molecular and functional spectra of ANKRD11 missense variants.
Methods We collected clinical information of individuals with ANKRD11 missense variants and evaluated phenotypic fit to KBG syndrome. We assessed pathogenicity of variants by in silico analyses and cell-based experiments.
Results We identified 29 individuals with (mostly de novo) ANKRD11 missense variants, who presented with syndromic neurodevelopmental disorders and were phenotypically similar to individuals with KBG syndrome caused by ANKRD11 protein truncating variants or 16q24.3 microdeletions. Missense variants significantly clustered in Repression Domain 2. Cellularly, most variants caused reduced ANKRD11 stability. One variant resulted in decreased proteasome degradation and loss of ANKRD11 transcriptional activity.
Conclusion Our study indicates that pathogenic heterozygous missense variants in ANKRD11 cause the clinically recognizable KBG syndrome. Disrupted transrepression capacity and reduced protein stability each independently lead to ANKRD11 loss-of-function, consistent with haploinsufficiency. This highlights the diagnostic relevance of ANKRD11 missense variants, but also poses diagnostic challenges, as the KBG-associated phenotype may be mild and inherited pathogenic ANKRD11 (missense) variants are increasingly observed, warranting stringent variant classification and careful phenotyping.
Competing Interest Statement
HZE and KZM are employees of GeneDx, Inc.
Funding Statement
This study was funded by Aspasia grants of the Dutch Research Council 015.014.036 to TK and 015.014.066 to LV, Netherlands Organization for Health Research and Development 91718310 to TK, and the Max Planck Society MW, SEF. Individual 4 was sequenced in the Scottish Genomes Partnership. The Scottish Genomes Partnership was funded by the Chief Scientist Office of the Scottish Government Health Directorates SGP 1 and The Medical Research Council Whole Genome Sequencing for Health and Wealth Initiative MC PC 15080. In addition, the collaborations in this study were facilitated by ERN ITHACA, one of the 24 European Reference Networks ERNs approved by the ERN Board of Member States, co-funded by European Commission. The aims of this study contribute to the Solve-RD project EdB, ASDP, LF, CG, TK, AV, LV which has received funding from the European Union Horizon 2020 research and innovation programme under grant agreement No 779257.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB Commissie Mensgebonden Onderzoek Regio Arnhem-Nijmegen of institution name Radboudumc gave ethical approval for this work under number 2011/188
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵¥ These authors jointly supervised the project
Disclosure HZE and KZM are employees of GeneDx, Inc. There are no other conflicts of interest.
Data Availability
Code used for spatial clustering is shared at https://github.com/laurensvdwiel/SpatialClustering. Code used for permutation testing is available at https://github.com/jhampstead/ANKRD11-simulations. For missense cases, all available phenotypic information in HPO terminology is shared as a supplementary file (Supplementary JSON). The HPO-data of individuals obtained from the Radboudumc Biobank are not publicly available due to IRB and General Data Protection Regulation (EU GDPR) restrictions. Access to these data may be requested from the data availability committee by contacting the corresponding author. Model and code for HPO-based clustering analysis are available at https://github.com/ldingemans/HPO_clustering_Wang. Figure 2, Table S2, Figure S1 and Supplementary JSON are not included in this preprint and are available from the corresponding author on request.
https://github.com/laurensvdwiel/SpatialClustering
